Drugs Made In America Acquisition Corp. Ordinary Shares

NASDAQ:DMAA

Shell Companies

Financial Services
$10.90 +0.00%

+$0.00 today

Market cap
$264.62M
Beta
0.00
P/E (TTM)
36.7
EPS (TTM)
$0.29
52W Low $10.17High $10.63

Volume 0.00M

Average 0.11M

DMAA Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQ: DMAA

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow declines year over year

Q1 FY2026 financing cash flow of $100K fell 100.0% year over year, in line with the -99.8% change in trailing-twelve-month financing cash flow. Sequentially, it fell 23.4% from the prior quarter.

What to watch

Whether quarterly growth recovers from -100.0% toward the trailing-twelve-month pace of -99.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$100K-23.4% QoQ
Last fiscal yearDec 2025
$231.69M+133352.0% YoY
LTMMar 2026
$393.16K-99.8% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+133352.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
231.69M USD
Year-over-year change
+133352.0%
1-year CAGR
+133352.0%

Financing Cash Flow vs competitors

How DMAA compares with its peers on the latest reported figures

  • DMAA's LTM Mar 2026 financing cash flow of $393.16K is the 8th largest of the 10 companies compared; the peer median is $233.75M.
  • Its year-over-year change of -99.8% is the 2nd highest of 3, against a peer median of -39.2%.
DMAA Competitors Peer median
Financing Cash Flow for DMAA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TACOUBerto Acquisition Corp. UnitFY2025$301.96M ———
TACOBerto Acquisition Corp.FY2025$301.96M ———
TACHTitan Acquisition Corp.LTM Mar 2026$278.75M ———
OYSEOyster Enterprises II Acquisition CorpFY2025$254.43M ———
LOKVLive Oak Acquisition Corp. V Class A Ordinary SharesFY2025$233.75M ———
RTACRenatus Tactical Acquisition Corp I Class A Ordinary SharesLTM Mar 2026$121.64M ———
SIMASIM Acquisition Corp. ILTM Mar 2026$702.26K +21.6%——
DMAADrugs Made In America Acquisition Corp. Ordinary SharesLTM Mar 2026$393.16K -99.8%——
ALFCenturion Acquisition Corp.LTM Mar 2026$0 ———
MLACMountain Lake Acquisition Corp.FY2025$0 -100.0%——
Peer median (excluding DMAA) $233.75M-39.2%——

Competitors are the stored peer set for DMAA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Drugs Made In America Acquisition Corp. Ordinary Shares

NASDAQ:DMAA

Intrinsic Alpha fair value

Locked

Current Price

$10.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.